There are no Transcripts on GNOM.
May. 8, 2012, 3:57 PM
Mar. 8, 2012, 6:25 PMComplete Genomics (GNOM) reverses late session gains to trade lower in the post session after reporting a Q4 loss of $0.67 per share, compared with the prior-year period's $0.69 loss per share. Revenues were $2.5M, down 34% from $3.8M in the same quarter last year. The Street was expecting a loss of $0.65 on revenues of $3.15M. Shares -2.1% AH. | Comment!
GNOM vs. ETF Alternatives
Other News & PR